Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judd W Moul

Showing results (1-10 of 312) with videos related to

Pageof 32
Sort By:
Urology|September 14, 2010
Editorial commentJudd W Moul
Urology|November 9, 2010
Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategyJudd W Moul
Cancer|June 2, 2009
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancerJudd W Moul
The Canadian Journal of Urology|April 30, 2014
Utility of LHRH antagonists for advanced prostate cancerJudd W Moul
The Journal of Urology|May 21, 2019
Editorial CommentJudd W Moul
The Journal of Urology|October 22, 2008
Are we overtreating prostate cancer?Judd W Moul
BJU International|March 13, 2009
Twenty-five year evolution of medical hormonal therapy for prostate cancerJudd W Moul
Urologic Oncology|December 30, 2008
Post-radical prostatectomy management options for positive surgical margins: argument for observationJudd W Moul
The Journal of Urology|June 7, 2016
Editorial CommentJudd W Moul
Oncology (Williston Park, N.Y.)|November 28, 2017
Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical ProstatectomyJudd W Moul
Pageof 32

Showing results (1-10 of 312) with videos related to

Sort By:
Pageof 32
Urology|September 14, 2010
Editorial commentJudd W Moul
Urology|November 9, 2010
Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategyJudd W Moul
Cancer|June 2, 2009
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancerJudd W Moul
The Canadian Journal of Urology|April 30, 2014
Utility of LHRH antagonists for advanced prostate cancerJudd W Moul
The Journal of Urology|May 21, 2019
Editorial CommentJudd W Moul
The Journal of Urology|October 22, 2008
Are we overtreating prostate cancer?Judd W Moul
BJU International|March 13, 2009
Twenty-five year evolution of medical hormonal therapy for prostate cancerJudd W Moul
Urologic Oncology|December 30, 2008
Post-radical prostatectomy management options for positive surgical margins: argument for observationJudd W Moul
The Journal of Urology|June 7, 2016
Editorial CommentJudd W Moul
Oncology (Williston Park, N.Y.)|November 28, 2017
Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical ProstatectomyJudd W Moul
Pageof 32